Literature DB >> 33725970

Primary pulmonary lymphoepithelioma-like carcinoma: A case report of pathological complete response (pCR) by neoadjuvant treatment.

Liqin Zhang1, Tairan Hao, Yuqing Wei, Mo Dong, Yuancheng Xiong.   

Abstract

RATIONALE: Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small cell lung cancer (NSCLC). It is predominantly reported in East Asia and currently there is no standard treatment for this disease. We report a case of stage IV PPLELC that achieved pathological complete response (pCR) by neoadjuvant treatment. PATIENT CONCERNS: The patient was a 46-year-old male who developed hemoptysis for about 20 ml of volume accompanied by cough and sputum after physical labor. DIAGNOSES: Contrast enhanced chest CT scanning showed occupation of left lower hilar area and left pleural effusion. Combined with medical history and auxiliary examination, the patient was formally diagnosed stage IV lymphoepithelioma-like carcinoma of the left lower lung (T3N0M1a pleura).
INTERVENTIONS: The patient was given Sintilimab combined with gemcitabine + nedaplatin chemotherapy (GP) regimen for four cycles with 3 weeks as a cycle, supplemented with antiemetics and stomach protection drugs to reduce chemotherapy-related side effects. OUTCOMES: After 4 cycles of treatment, the patient's left lung lesion has been markedly reduced and the left pleural effusion has also been significantly absorbed. Remarkably, surgical biopsies found no cancer cells in the lesion site and postoperative pathology showed complete pathological remission (pCR). LESSONS: We reported a case of PPLELC that is sensitive to neoadjuvant treatment, showing excellent effectiveness and safety and achieving pCR.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 33725970      PMCID: PMC7982184          DOI: 10.1097/MD.0000000000024987

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  16 in total

1.  Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung.

Authors:  L R Bégin; J Eskandari; J Joncas; L Panasci
Journal:  J Surg Oncol       Date:  1987-12       Impact factor: 3.454

2.  Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden.

Authors:  Qian Wu; Weiya Wang; Ping Zhou; Yiyun Fu; Ying Zhang; Yang W Shao; Lili Jiang
Journal:  Pathol Res Pract       Date:  2020-06-02       Impact factor: 3.250

Review 3.  Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: A case report and review of the literature.

Authors:  Zhengwu Tang; Rui Fang; Guihui Tong; Peng Liu; Zhu'an Ou; Yong Tang
Journal:  Lung Cancer       Date:  2020-06-24       Impact factor: 5.705

4.  Association of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the lung in southern China.

Authors:  A J Han; M Xiong; Y S Zong
Journal:  Am J Clin Pathol       Date:  2000-08       Impact factor: 2.493

5.  Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up.

Authors:  Ying Liang; Liang Wang; Yujia Zhu; Yongbin Lin; Hui Liu; Huilan Rao; Guangchuan Xu; Tiehua Rong
Journal:  Cancer       Date:  2012-02-22       Impact factor: 6.860

6.  Lack of epidermal growth factor receptor gene mutations in exons 19 and 21 in primary lymphoepithelioma-like carcinoma of the lung.

Authors:  Qianwen Liu; Guowei Ma; Haoxian Yang; Jing Wen; Mei Li; Hong Yang; Kongjia Luo; Yi Hu; Jianhua Fu
Journal:  Thorac Cancer       Date:  2014-01-02       Impact factor: 3.500

7.  Detection of rearrangement of anaplastic lymphoma kinase (ALK) and mutation of epidermal growth factor receptor (EGFR) in primary pulmonary lymphoepithelioma-like carcinoma.

Authors:  Liang Wang; Yongbin Lin; Qingqing Cai; Hao Long; Yu Zhang; Tiehua Rong; Guowei Ma; Ying Liang
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

8.  Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).

Authors:  Yunpeng Yang; Zhehai Wang; Jian Fang; Qitao Yu; Baohui Han; Shundong Cang; Gongyan Chen; Xiaodong Mei; Zhixiong Yang; Rui Ma; Minghong Bi; Xiubao Ren; Jianying Zhou; Baolan Li; Yong Song; Jifeng Feng; Juan Li; Zhiyong He; Rui Zhou; Weimin Li; You Lu; Yingyi Wang; Lijun Wang; Nong Yang; Yan Zhang; Zhuang Yu; Yanqiu Zhao; Conghua Xie; Ying Cheng; Hui Zhou; Shuyan Wang; Donglei Zhu; Wen Zhang; Li Zhang
Journal:  J Thorac Oncol       Date:  2020-08-08       Impact factor: 15.609

9.  The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma.

Authors:  Shaodong Hong; Dongbing Liu; Shuzhen Luo; Wenfeng Fang; Jianhua Zhan; Sha Fu; Yaxiong Zhang; Xuan Wu; Huaqiang Zhou; Xi Chen; Gang Chen; Zhonghan Zhang; Qiufan Zheng; Xiaobo Li; Jinghao Chen; Xingmin Liu; Mengyue Lei; Chen Ye; Jian Wang; Huanming Yang; Xun Xu; Shida Zhu; Yunpeng Yang; Yuanyuan Zhao; Ningning Zhou; Hongyun Zhao; Yan Huang; Lanjun Zhang; Kui Wu; Li Zhang
Journal:  Nat Commun       Date:  2019-07-16       Impact factor: 14.919

10.  [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].

Authors:  Hui Zhao; Jianhua Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.